Roche presents new data from its bispecific antibody portfolio across a range of blood cancers

Roche today announced that new data on its investigational T-cell engaging bispecific antibodies, mosunetuzumab, glofitamab and cevostamab, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, from 5-8 December 2020, showing encouraging activity across multiple types of blood cancer.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news